



## **Mentara Bio Initiates Phase 2 Study of MN-301, an Innovative Antiepileptic Compound**

DURHAM, NORTH CAROLINA, UNITED STATES, May 13, 2024 /EINPresswire.com/ -- Mentara Bio, a clinical-stage biopharmaceutical company focused on developing neurocircuit-selective medicines for neurological disorders, announced today its plans to commence a Phase 2 clinical trial of MN-301 for the treatment of epilepsy. MN-301 is a novel, highly selective compound targeting specific receptors involved in epilepsy pathways, developed in collaboration with leading academic institutions.

“Advancing MN-301 into Phase 2 clinical trials represents a significant milestone in our commitment to addressing the urgent unmet needs of epilepsy patients,” said Sahil Velivelli, Chief Executive Officer of Mentara Bio. “The innovative mechanism of action of MN-301 holds promise for improving treatment outcomes while minimizing side effects commonly associated with current therapies.”

MN-301 selectively modulates key neurocircuit pathways implicated in epilepsy, offering a potential breakthrough in treatment by enhancing inhibitory signaling without the broad activity seen in conventional antiepileptic drugs. The compound has demonstrated promising safety and efficacy profiles in preclinical studies, laying a robust foundation for advancing into clinical trials.

“We are enthusiastic about the potential of MN-301 to provide a new therapeutic option for patients suffering from epilepsy,” commented Dr. Nick Kwan, Chief Medical Officer of Mentara Bio. “The Phase 2 study aims to build upon our positive Phase 1 results and further evaluate the clinical benefits of MN-301 in managing epileptic seizures.”

Epilepsy affects millions worldwide, with a substantial portion of patients facing inadequate seizure control and adverse effects from current therapies. MN-301’s targeted approach aims to address these challenges, potentially improving quality of life for epilepsy patients and their families.

### **About Mentara Bio**

Mentara Bio is a clinical-stage biopharmaceutical company dedicated to developing innovative neurocircuit-selective medicines for neurological disorders. Our lead candidate, MN-301, is a novel antiepileptic compound designed to modulate specific neurocircuit pathways implicated in epilepsy. For more information, please visit [www.mentarabio.com](http://www.mentarabio.com) and connect with us on Twitter and LinkedIn.

### **Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Prospective investors are cautioned not to place undue reliance on these forward-looking statements. Mentara Bio undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.



For further information, contact:

Sahil Velivelli, PhD, MBA  
Mentara Bio Inc., President and CEO  
[Sahil.velivelli@mentarabio.com](mailto:Sahil.velivelli@mentarabio.com) or  
Email: [info@mentarabio.com](mailto:info@mentarabio.com)